Pools of programmed death‐ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies
Authors:
- 9 April 2016
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 38 (8) , 1176-1186
Abstract
Background: Enhanced understanding of programmed death‐ligand (PD‐L) expression in oral cancer is important for establishing rational combinations of emerging immune checkpoint and molecular targeted therapies.Methods: We assessed PD‐L and interferon (IFN) expression in immunogenic murine oral cancer‐1 (MOC1) and poorly immunogenic MOC2 cell models after treatment with mammalian target of rapamycin (mTOR) and MEK1/2 small molecule inhibitors in vitro and in vivo.Results: PD‐L1 but not PD‐L2 is expressed on MOC1 and 2 cells and is type I and II IFN‐dependent. PD‐L1 is differentially expressed on cancer and endothelial cells and infiltrating myeloid‐derived suppressor cells, macrophages, and regulatory T cells (Tregs) in highly and poorly immunogenic tumors. PD‐L1 expression is variably altered after treatment with inhibitors in vivo, with an imperfect relationship to alterations in IFN levels in the tumor microenvironment.Conclusion: PD‐L1 expressed on cancer and infiltrating immune cells is variably altered by targeted therapies and may, in part, reflect changes in tumor IFN. © 2016 Wiley Periodicals, Inc. Head Neck 38:1176–1186, 2016Keywords
This publication has 30 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expressionOncology Letters, 2013
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsJournal of Clinical Investigation, 2012
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Comparative Analysis of Tumor‐Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral CancerOtolaryngology–Head and Neck Surgery, 2012
- ERK1/2 Regulation of CD44 Modulates Oral Cancer AggressivenessCancer Research, 2012
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysisEuropean Journal of Immunology, 2003